Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,615 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Application of the model-informed drug development paradigm to datopotamab deruxtecan dose selection for late-stage development.
Lu Y, Liang S, Hong Y, Tajima N, Patel K, Li H, Wada DR, Greenberg J, Petrich A, Zebger-Gong H, Shuster D, Vaddady P. Lu Y, et al. Among authors: greenberg j. CPT Pharmacometrics Syst Pharmacol. 2024 Jan;13(1):23-28. doi: 10.1002/psp4.13058. Epub 2023 Nov 1. CPT Pharmacometrics Syst Pharmacol. 2024. PMID: 37915242 Free PMC article. Clinical Trial.
Exposure-response analysis of efficacy and safety for pexidartinib in patients with tenosynovial giant cell tumor.
Yin O, Zahir H, French J, Polhamus D, Wang X, van de Sande M, Tap WD, Gelderblom H, Wagner AJ, Healey JH, Greenberg J, Shuster D, Stacchiotti S. Yin O, et al. Among authors: greenberg j. CPT Pharmacometrics Syst Pharmacol. 2021 Nov;10(11):1422-1432. doi: 10.1002/psp4.12712. Epub 2021 Oct 14. CPT Pharmacometrics Syst Pharmacol. 2021. PMID: 34585528 Free PMC article.
Dosing Recommendation Based on the Effects of Different Meal Types on Pexidartinib Pharmacokinetics in Healthy Subjects: Implementation of Model-informed Drug Development Strategy.
Zahir H, Yin O, Hsu C, Wagner AJ, Jiang J, Wang X, Greenberg J, Shuster DE, Kakkar T, LaCreta F. Zahir H, et al. Among authors: greenberg j. Clin Pharmacol Drug Dev. 2023 May;12(5):475-483. doi: 10.1002/cpdd.1240. Epub 2023 Mar 21. Clin Pharmacol Drug Dev. 2023. PMID: 36942508
Effect of Mild and Moderate Hepatic Impairment (Defined by Child-Pugh Classification and National Cancer Institute Organ Dysfunction Working Group Criteria) on Pexidartinib Pharmacokinetics.
Zahir H, Greenberg J, Hsu C, Marbury TC, Lasseter KC, Xu LA, Tap WD, Healey JH, Stacchiotti S, LaCreta F. Zahir H, et al. Among authors: greenberg j. J Clin Pharmacol. 2022 Aug;62(8):992-1005. doi: 10.1002/jcph.2042. Epub 2022 Mar 31. J Clin Pharmacol. 2022. PMID: 35247274 Free PMC article.
Impact of race on dose selection of molecular-targeted agents in early-phase oncology trials.
Yokota T, Bendell J, LoRusso P, Tsushima T, Desai V, Kenmotsu H, Watanabe J, Ono A, Murugesan B, Silva J, Naito T, Greenberg J, Kumar P, Wang Y, Jikoh T, Shiga R, Hyman DM, Ho AL, Spriggs DR, Schwartz GK, Gounder MM. Yokota T, et al. Among authors: greenberg j. Br J Cancer. 2018 Jun;118(12):1571-1579. doi: 10.1038/s41416-018-0102-1. Epub 2018 May 24. Br J Cancer. 2018. PMID: 29795308 Free PMC article. Clinical Trial.
2,615 results